(2R)-2-哌啶乙酸 | 19832-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (2R)-2-哌啶乙酸
• 英文名称: (R)-2-(piperidin-2'-yl)ethanoic acid
• 英文别名: (R)-2-(piperidin-2-yl)ethanoic acid；(2R)-(piperidin-2-yl)acetic acid；(2R)-2-carboxymethylpiperidine；(R)-2-piperidineacetic acid；(2R)-Homopipecolinsaeure；R-(-)-homopipecolic acid；(R)-2-(Piperidin-2-yl)acetic acid；2-[(2R)-piperidin-2-yl]acetic acid
• CAS: 19832-04-3；55049-18-8；64625-19-0；69222-96-4
• 化学式: C₇H₁₃NO₂
• mdl: MFCD02667638
• 分子量: 143.186
• InChiKey: PRNLNZMJMCUWNV-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  、 (2R)-2-哌啶乙酸 在 lithium hexamethyldisilazane 、 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

  摘要：

  The increasing dissemination of carbapenemases in Gram-negative bacteria has threatened the clinical usefulness of the beta-lactam class of antimicrobials. A program was initiated to discover a new series of serine beta-lactamase inhibitors containing a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials. Potential lead structures were screened in silico by modeling into the active sites of key serine beta-lactamases. Promising candidate molecules were synthesized and evaluated in biochemical and whole-cell assays. Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases. Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains. Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-negative bacteria.

  DOI：

  10.1021/acs.jmedchem.5b00127
• 作为产物：
  描述：

  1,3-丙酮二羧酸 在 盐酸 、 三乙基硅烷 、 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochlorite 、 disodium hydrogenphosphate 、 三氟化硼乙醚 、 碳酸氢钠 、 potassium carbonate 、 一水合肼 、 间氯过氧苯甲酸 、 potassium bromide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 54.08h， 生成 (2R)-2-哌啶乙酸
  参考文献：
  名称：

  Syntheses of (−)-pelletierine and (−)-homopipecolic acid

  摘要：

  通过手性拆分四氢呋喃，然后进行拜耳-维利格氧化，实现了（∘）-高哌啶酸和（∘）-佩利替林的对应体合成。该方法为光学纯哌啶的合成提供了切实可行的途径。

  DOI：

  10.1039/c2ob06984a

文献信息

• Novel piperidine compouds and drugs containing the same
  申请人：——

  公开号：US20030220368A1

  公开（公告）日：2003-11-27

  The present invention provides a novel compound having a superior Na + channel inhibition activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. 1 In the formula, the ring A represents a ring represented by the formula: 2 (wherein R 1 represents a hydrogen atom etc.; and R 2 represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C 1-6 alkylene group etc.; Z represents an optionally substituted C 6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.

  本发明提供了一种具有优越的Na + 通道抑制活性的新型化合物。即提供了由以下式（I）表示的化合物，其盐或其水合物。 在该式中，环A表示由以下式表示的环： （其中R 1 表示氢原子等；R 2 表示表示氢原子等）等；W表示可选地取代的C 1-6 烷基等；Z表示可选地取代的C 6-14 芳香烃环基等；l表示0到6的整数。
• An Efficient Synthesis of Chiral Cyclic β-Amino Acids via Asymmetric Hydrogenation
  作者：Cyrille Pousset、Marc Larchevêque、Roland Callens、Angela Marinetti

  DOI：10.1055/s-2004-835659

  日期：——

  Cyclic p-amino acids, homoproline, homopipecolic acid and 3-carboxy-methylmorpholine were obtained in high enantiomeric excesses by transition metal-catalyzed asymmetric hydrogenation of cyclic β-acylamino-alkenoates. These compounds were synthesized by a thio-Wittig reaction on N-protected thiolactames.

  通过过渡金属催化的环状β-酰基氨基-烯酸酯的不对称氢化，以高对映体过量获得环状p-氨基酸、高脯氨酸、高哌啶酸和3-羧基-甲基吗啉。这些化合物是通过在 N 保护的硫代内酰胺上的硫代-维蒂希反应合成的。
• Improved Protocol for Asymmetric, Intramolecular Heteroatom Michael Addition Using Organocatalysis: Enantioselective Syntheses of Homoproline, Pelletierine, and Homopipecolic Acid
  作者：Erik C. Carlson、Lauren K. Rathbone、Hua Yang、Nathan D. Collett、Rich G. Carter

  DOI：10.1021/jo800749t

  日期：2008.7.1

  indoline, and piperidine rings using an organocatalyzed, intramolecular heteroatom Michael addition is described. Application to the enantioselective synthesis of homoproline, homopipecolic acid, and pelletierine has been accomplished.

  描述了使用有机催化的分子内杂原子迈克尔加成构建对映体富集的吡咯烷、二氢吲哚和哌啶环的改进方案。已完成对高脯氨酸、高哌可酸和匹莱林的对映选择性合成的应用。
• [EN] PROCESS FOR THE ENANTIOSELECTIVE PRODUCTION OF AN AMINO ACID DERIVATIVE COMPRISING AT LEAST ONE NITROGENOUS HETEROCYCLE<br/>[FR] PROCEDE DE PRODUCTION DE DERIVE D'ACIDE AMINE DE MANIERE ENANTIOSELECTIVE COMPRENANT AU MOINS UN HETEROCYCLE AZOTE
  申请人：SOLVAY

  公开号：WO2004087661A1

  公开（公告）日：2004-10-14

  Process for the enantioselective production of an amino acid derivative comprising at least one nitrogenous heterocycle, said heterocycle being substituted with at least one side chain comprising a functional group of carboxyl type, such as a carboxyl group, an ester group or an amide group, which process comprises at least one step in which a prochiral unsaturated amino acid derivative of formula (I) is subjected to hydrogenation in the presence of an enantiopure hydrogenation catalyst.

  进行具有至少一个含氮杂环的氨基酸衍生物的对映选择性生产的过程，所述杂环被至少一个侧链取代，所述侧链包括羧基功能团，例如羧基、酯基或酰胺基，该过程包括至少一个步骤，其中式(I)的非手性不饱和氨基酸衍生物在存在对映纯氢化催化剂的情况下经过氢化。
• [EN] GLYCINE METABOLISM MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DU MÉTABOLISME DE LA GLYCINE ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2018021977A1

  公开（公告）日：2018-02-01

  The present invention relates to a compound of general formula (I) and/or its solvates, hydrates and pharmaceutically acceptable salts, which are modulators of glycine metabolism. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with glycine metabolism or a pathway where glycine decarboxylase (GLDC, or glycine cleavage system) plays a role. In a preferred embodiment the disorders/conditions/disease is cancer, inflammatory conditions, Alzheimer's disease, metabolic disorders and CNS disorders.

  本发明涉及一般式(I)的化合物及/或其溶剂合物、水合物和药学上可接受的盐，这些化合物是甘氨酸代谢调节剂。本发明还涉及其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗涉及或与甘氨酸代谢或甘氨酸脱羧酶（GLDC，或甘氨酸裂解系统）发挥作用的病症/疾病/疾病的用途。在一个首选实施例中，疾病/疾病是癌症、炎症性疾病、阿尔茨海默病、代谢性疾病和中枢神经系统疾病。